Top-Rated StocksTop-RatedNYSE:PRME Prime Medicine (PRME) Stock Price, News & Analysis $3.55 -0.20 (-5.33%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$3.47▼$3.7950-Day Range$3.55▼$6.7052-Week Range$3.47▼$13.27Volume692,261 shsAverage Volume753,251 shsMarket Capitalization$426.11 millionP/E RatioN/ADividend YieldN/APrice Target$14.11 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get Prime Medicine alerts: Email Address Prime Medicine MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside297.5% Upside$14.11 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.67Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.76) to ($1.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.74 out of 5 starsMedical Sector383rd out of 910 stocksBiological Products, Except Diagnostic Industry55th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingPrime Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePrime Medicine has only been the subject of 2 research reports in the past 90 days.Read more about Prime Medicine's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for PRME. Previous Next 0.0 Dividend Strength Dividend YieldPrime Medicine does not currently pay a dividend.Dividend GrowthPrime Medicine does not have a long track record of dividend growth.Read more about Prime Medicine's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRME. Previous Next 3.2 News and Social Media Coverage News SentimentPrime Medicine has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Prime Medicine this week, compared to 3 articles on an average week.Search Interest3 people have searched for PRME on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Prime Medicine to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prime Medicine insiders have not sold or bought any company stock.Percentage Held by Insiders24.29% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prime Medicine's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Prime Medicine are expected to grow in the coming year, from ($1.76) to ($1.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prime Medicine is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prime Medicine is -1.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrime Medicine has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Prime Medicine's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Mode MobilePre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.Claim Exclusive 100% Bonus: $0.25/Share About Prime Medicine Stock (NYSE:PRME)Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Read More PRME Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRME Stock News HeadlinesSeptember 5 at 1:01 AM | americanbankingnews.comAnalysts Set Prime Medicine, Inc. (NYSE:PRME) Price Target at $14.70September 4 at 10:21 AM | seekingalpha.comPrime Medicine's Promising Pipeline: PM359 And Cash Burn ConcernsSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine, Inc. on Strong Clinical Trials and Financial FootingAugust 9, 2024 | markets.businessinsider.comPRME Stock Earnings: Prime Medicine Misses EPS for Q2 2024August 8, 2024 | finance.yahoo.comPrime Medicine Reports Second Quarter 2024 Financial Results and Provides Business UpdatesJuly 8, 2024 | insidermonkey.comPrime Medicine, Inc. (PRME): Why Do Analysts Love This Shorted Stock Right Now?June 20, 2024 | seekingalpha.comPrime Medicine Stock: Only For The Most Patient Of InvestorsSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.May 29, 2024 | investorplace.comIf You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 NamesMay 25, 2024 | fool.comHere Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion PortfolioMay 24, 2024 | finance.yahoo.comPrime Medicine, Inc. (PRME)May 21, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Prime Medicine (PRME) with Buy RecommendationMay 17, 2024 | msn.comCitigroup Upgrades Prime Medicine (PRME)May 17, 2024 | investorplace.comWall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024May 17, 2024 | investorplace.comWall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024May 15, 2024 | msn.comWhat is Prime Day, exactly? How Amazon's giant deals day worksMay 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prime Medicine, Inc. on FDA Trial Approval and Strong FinancialsSee More Headlines Receive PRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:PRME CUSIPN/A CIK1894562 Webprimemedicine.com Phone617-564-0013FaxN/AEmployees234Year FoundedN/APrice Target and Rating Average Stock Price Target$14.11 High Stock Price Target$20.00 Low Stock Price Target$9.00 Potential Upside/Downside+297.5%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-198,130,000.00 Net MarginsN/A Pretax Margin-36,809.98% Return on Equity-106.30% Return on Assets-81.24% Debt Debt-to-Equity RatioN/A Current Ratio8.23 Quick Ratio8.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book2.59Miscellaneous Outstanding Shares120,030,000Free Float90,875,000Market Cap$426.11 million OptionableOptionable Beta2.19 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Keith Michael Gottesdiener Ph.D. (Age 70)President, CEO, Secretary & Director Comp: $924.04kDr. Ann L. Lee Ph.D. (Age 62)Chief Technical Officer Comp: $947.28kMr. Richard Brudnick (Age 66)Chief Business Officer Comp: $680.8kDr. Andrew Anzalone M.D. (Age 37)Ph.D., Co-Founder & Head of Prime Editing Platform Dr. David R. Liu Ph.D.Co-Founder & Chair of Scientific Advisory BoardDr. Allan Reine M.D. (Age 49)Chief Financial Officer Dr. Meredith Goldwasser (Age 52)Senior VP and Head of Strategy & Corporate Operations Ms. Carman Alenson CPA (Age 58)M.B.A., Senior VP of Finance & Chief Accounting Officer Dr. Jeremy S. Duffield M.D. (Age 56)Ph.D., Chief Scientific Officer Comp: $994.4kDr. Karen Brown J.D.Ph.D., Senior Vice President of Intellectual Property & Legal AffairsMore ExecutivesKey CompetitorsImmunocoreNASDAQ:IMCRNeumora TherapeuticsNASDAQ:NMRABioCryst PharmaceuticalsNASDAQ:BCRXNovavaxNASDAQ:NVAXRecursion PharmaceuticalsNASDAQ:RXRXView All CompetitorsInsiders & InstitutionsDeerfield Management Company L.P. Series CBought 11,646 shares on 8/15/2024Ownership: 0.747%Susquehanna Fundamental Investments LLCBought 28,204 shares on 8/15/2024Ownership: 0.041%AQR Capital Management LLCBought 34,268 shares on 8/15/2024Ownership: 0.029%Susquehanna Portfolio Strategies LLCSold 87,640 shares on 8/15/2024Ownership: 0.024%The Manufacturers Life Insurance Company Sold 50,790 shares on 8/15/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions PRME Stock Analysis - Frequently Asked Questions How have PRME shares performed this year? Prime Medicine's stock was trading at $8.86 at the beginning of the year. Since then, PRME stock has decreased by 59.9% and is now trading at $3.55. View the best growth stocks for 2024 here. How were Prime Medicine's earnings last quarter? Prime Medicine, Inc. (NYSE:PRME) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.40) by $0.06. When did Prime Medicine IPO? Prime Medicine (PRME) raised $175 million in an initial public offering (IPO) on Thursday, October 20th 2022. The company issued 10,294,118 shares at a price of $16.00-$18.00 per share. Who are Prime Medicine's major shareholders? Top institutional investors of Prime Medicine include ARK Investment Management LLC (5.10%), Sumitomo Mitsui Trust Holdings Inc. (2.70%), Millennium Management LLC (1.11%) and Deerfield Management Company L.P. Series C (0.75%). Insiders that own company stock include Robert Nelsen and 2019 Gp LLC Gv. View institutional ownership trends. How do I buy shares of Prime Medicine? Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:PRME) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
